Skip to NavigationSkip to content

brexit

Top Ten most popular articles on Pharmafile.com this week

Business, biosimilars and Brexit are the themes of this week’s top 10. While Roche signed a $1 billion deal with SQZ Biotech, MSD’s and Samsung Bioepis’ deal fell through. Meanwhile Pfizer announced a cull of 2% of its staff amid a widespread restructuring.

AstraZeneca halting UK investment due to Brexit uncertainty

The Anglo-Swedish pharma firm AstraZeneca has suspended investment into the United Kingdom, due to the uncertainty surrounding Brexit.

The firm’s non-executive chairman, Leif Johansson, shed light on the company’s decision, in an interview with French newspaper Le Monde.

“If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest,” the Swedish businessman said to Le Monde.

MHRA to consult on potential for no-deal Brexit

The Medicines and Healthcare products Regulatory Agency (MHRA) has opened a consultation on how its legislation and regulatory processes would be impacted by a no-deal Brexit.

The agency have said in a statement that although they “remain committed” to the negotiation of an agreement with the European Union, they believe “a responsible government should prepare for all potential outcomes, including the unlikely scenario in which no mutually satisfactory agreement can be reached.”

Survey reveals 56% gender pay gap between doctors in NHS

Male doctors in the United Kingdom earn 56% more than their female counterparts, according to a survey conducted by Medscape. While full-time female physicians earn an average of £80,000 per annum, the average salary is £126,400 for men.

The figure contradicts data released by the NHS earlier this year which suggests there is a 21.2% pay gap between male and female physicians.

Clinical trial halted because of Brexit, UK Government downplays concerns

A clinical trial looking into the safety and efficacy of the drug dutogliptin has been halted due to uncertainties surrounding Brexit.

The trial, which was being undertaken by US-based research firm Recardio in the British towns and cities of Leeds, Exeter and Clydebank, was stopped due to regulatory concerns associated with Brexit.

EMA says pharma industry now more prepared for Brexit

In July of this year the European Medicines Agency (EMA) identified significant gaps in the pharmaceutical industry’s preparedness for Brexit. However, since then much progress has been made, as the number of medicines that it is believed could be subject to disruption has dropped from 108 to 39, according to the European regulator.

Top Ten most popular articles on Pharmafile.com this week

With the Pharmafocus team having avoided hurricane Florence and finally arriving back in the UK just last night, after stopping by the FlyPharma 2018 Conference in Miami, FLA it’s time to look over this week’s top ten most popular news stories.

Topping the list is the news that FDA recruitment official Melanie Keller has said that Trump is making it difficult to attract top talent; a claim which has been disputed by others inside the organisation.

Novo Nordisk stockpiles 16 weeks' worth of insulin in preparation for hard Brexit

Image Credit: SimpleSimpleSimple https://commons.wikimedia.org/wiki/File:Novo_Nordisk_headquarters_building_Denmark.jpg

Danish multinational Novo Nordisk has announced that they are increasing their stocks of insulin products to ensure that there are 16 weeks’ worth of supplies, in preparation for a hard no deal Brexit. 

The announcement has come after the UK’s health secretary Matt Hancock told pharmaceutical companies to stockpile medicines in preparation for a hard exit from the European Union.

Drug safety: UK and EU post-Brexit

Published on 10/09/18 at 01:05pm

What does Brexit mean for drug safety in Europe and the United Kingdom? Louis Goss looks into Britain’s exit from the European Union and asks what the future might hold for pharmacovigilance on both sides of the channel.

It could be said that current notions of drug safety and pharmacovigilance were first developed in Britain. The ‘Apothecary Wares, Drugs and Stuffs Act’, passed by Henry VIII in 1540, was the first official act aimed at ensuring the safety of drugs and medicines.

Top Ten most popular articles on Pharmafile.com this week

Brexit took the top two spots this week after it was revealed that the EMA has awarded Britain's MHRA just two contracts this year, while GSK complained that Brexit will cost them $100 million. Meanwhile scandals have soured the first week of September as Sanofi settled charges of corruption with a $25 million dollar payment to the US while Dutch doctors campaigned against the price hiking Italian firm Leadiant Biosciences.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches